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To the Editor,
Primary hyperparathyroidism (PHP), the excretion of 
abnormal amounts of parathyroid hormone (PTH) rela-
tive to serum calcium levels, is most often caused by para-
thyroid adenoma (80–85% of cases) [1]. When indicated, 
surgery remains the only curative intervention for PHP [2]. 
When performed by an experienced surgeon, cure rates 
are high and may approach 100% [3]. Intraoperative PTH 
measurements are a cornerstone in the surgical strategy 
for PHP [4]. Although multiple criteria for success have 
been defined (reviewed in [4]), fast PTH measurements 
are required for optimal use. This optimal use may not 
stem from patient outcome, as this is similar for fast and 
standard-length PTH assays in patients with monoglan-
dular disease [5], but on reduced time in the operation 
theatre [6]. Also, one may hypothesise that patients suf-
fering from causes other than monoglandular forms of 
hyperparathyroidism will benefit from fast turnaround 
times as the surgeon will be able to act faster to a lack of 
decrease in PTH.
Typically, decay in PTH is measured and timing is set 
to 10–20  min after resection. At this moment, only few 
marketed options are widely available [7]. Abbott’s Archi-
tect, Siemens Advia Centaur and Beckman’s Access intact 
PTH assays are available but have relatively long incuba-
tion times (time-to-result: 18 min). Also, these machines 
are commonly found in the core laboratory and thus 
necessitate sample transport. Shorter incubation times 
can be achieved using Roche’s Elecsys (time-to-result: 9) 
which is commonly found in the core laboratory and 
Future Diagnostics’ point-of-care IO-PTH package which 
can be brought up to the patient’s bedside (time-to-result: 
8 min).
Here, we describe a modified intact PTH measure-
ment protocol with shorter incubation times that can be 
implemented on IDS’s ISYS automated immunoassay plat-
form (IDS, Boldon, UK). The standard incubation times 
(first, 26 min and s, 10 min) were shortened to 7 min and 
3  min, respectively. This protocol was compared to the 
standard protocol in left-over samples from routine meas-
urements (n = 71) as well as samples collected during par-
athyroid surgery (n = 51) of patients suffering from PHP. 
Ultimately, measurements of both the non-modified (IVD) 
and modified (LDT) assays were compared to results from 
a Future Diagnostics IO-PTH analyser (Future Diagnostics, 
Wijchen, The Netherlands) as well as a third- generation 
PTH assay on a Fujirebio Lumipulse G1200 analyser 
(Fujirebio, Tokyo, Japan).
Measurement variation of the LDT was CV 9.5% (mean 
5.5 pM) and CV 6.7% (mean 105.5 pM), in 21 separate runs. 
This was comparable to the CV% found for other IO-PTH 
platforms [7]. Measurement uncertainty of the IVD assay 
was CV 6.7% at 6.5 pM and CV 8.0% at 119.0 pM. Long-
term measurement uncertainty of the FD assay was not 
assessed by retrospective analysis as each kit comes with 
new controls. From the literature, it was derived that the 
intra-assay CV% is 23.5% for this platform [7]. Measure-
ment uncertainty of the Lumipulse assay was CV 4.9% 
(mean 2.1 pM) and CV 6.7% (mean 40.4 pM), in 24 separate 
runs.
In leftover samples, a small proportional bias was 
found between IVD and LDT assays (β = 97%, 95% CI 96–
99%, Figure 1A). Also, a small absolute bias (α = 0.3 pM, 
95% CI 0.1–0.4 pM) was found. Both findings were most 
likely due to the fact that the IVD and LDT assays were 
*Corresponding author: Sjoerd A.A. van den Berg, Department of 
Clinical Chemistry and Department of Internal Medicine, Erasmus 
Medical Centre, Room Na408, Doctor Molewaterplein 40, 3015 GD 
Rotterdam, The Netherlands, E-mail: s.a.a.vandenberg@erasmusmc.nl 
Ulfar G. Doelman, Hans van Toor and Piet Uitterlinden: Department 
of Internal Medicine, Erasmus Medical Centre, Rotterdam, The 
Netherlands
Tessa M. van Ginhoven and Gaston J. Franssen: Department of 
Surgery, Erasmus Medical Centre, Rotterdam, The Netherlands
 Open Access. © 2020 Sjoerd A.A. van den Berg et al., published by De Gruyter.  This work is licensed under the Creative Commons Attribution 4.0  
Public License.
2      Doelman et al.: Modified iPTH on IDS-ISYS for intraoperative measurements
run on different machines, and the magnitude of bias was 
deemed clinically irrelevant as it fell well within the inter-
mediate precision of the IVD assay. In surgical patient 
samples, a similar proportional bias was seen (β = 96%, 
95% CI 92–99%, Figure 1B) in addition to a small absolute 
bias (α = −0.5 pM, 95% CI −0.8 to −0.1 pM). Together, these 
data show that the IDS-ISYS LDT can be used interchange-
ably with the IVD assay.
Taking these data, we used the LDT as the standard 
and compared outcomes, both absolute and relative, 
to a dedicated IO-PTH platform (FD). When comparing 
absolute data, a significant proportional bias was seen 
(β = 271%, 95% CI 234–308%, data not shown), which 
was expected from previous findings by others [8]. Also, 
we found an absolute bias (α = 2.5 pM, –3.3 pM, data not 
shown). These data prevent the use of the IDS-ISYS LDT 
and FD assays interchangeably.
Based on these data, we tested whether the LDT 
would result in similar outcomes in terms of percentage 
decrease in PTH when compared to the IVD. As expected, 
when expressed as %decrease of PTH in time, the IVD and 
LDT produce similar results. The proportional bias was 
significant (β = 101%, 95% CI 100–101%, Figure 2A) but 
deemed irrelevant given its magnitude. No absolute bias 
was found (α = 2%, 95% CI 0–3%).
Finally, we used the LDT to predict outcome of the FD 
assay. Although the absolute results of the assays were dif-
ferent, the results of the LDT and FD assay were similar 
in terms of %decrease in PTH. No proportional bias was 
found (β = 105%, 95% CI 100–110%, Figure 2B). Also, no 
absolute bias was found (α = −2%, 95% CI −4% to 0%).
Given the nature of the disease and intervention 
performed, it is reduction in production of PTH and not 
reduction in circulating fragment concentration that 
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Figure 2: Decrease in parathyroid hormone (PTH) during parathyroid surgery.
(A) PTH was measured using IDS-ISYS employing the manufacturer provided protocol (X-axis) vs. an adapted protocol (Y-axis). (B) PTH was 
measured using IDS-ISYS employing the adapted protocol (X-axis) vs. measurement of PTH on a dedicated intra-operative PTH measurement 
platform (Future Diagnostics IO-PTH (Y-axis). Adaptation of the IDS-ISYS protocol was based in shortening the incubation steps from 26 and 
10 min to 7 and 3 min, respectively.
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Figure 1: Parathyroid hormone (PTH) measured using IDS-ISYS employing the manufacturer provided protocol (X-axis) vs. an adapted 
protocol (Y-axis). Adaptation was based in shortening the incubation steps from 26 and 10 min to 7 and 3 min, respectively.
(A) PTH measured in left over samples of non-surgical patients. (B) PTH measured in left over samples of patients during parathyroid surgery.
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causes the decrease in PTH concentration. This was 
confirmed by measuring PTH in all samples using a 
third- generation PTH assay which specifically measures 
PTH1-84, the mature hormone released by the parathyroid 
gland. As hypothesised, the decrease in PTH seen with 
the third-generation assay was similar to the decrease 
in the LDT; there was no proportional (β = 102%, 95% CI 
93–110%, data not shown) or absolute bias (α = −8%, 95% 
CI −11 to 3%, data not shown). We must, however, keep 
in mind that our study only included patients with PHP. 
Comparability of results between platforms may differ in 
patients with reduced kidney function and accompanied 
impairments of PTH fragments when using second- (but 
not third-) generation PTH assays [9].
Together, these data show that an incubation time-
modified IDS-ISYS intact PTH can be used for intraopera-
tive PTH measurements in patients suffering from PHP. 
The modified IDS assay had no bias when compared to the 
IDS IVD assay in samples collected randomly or during 
parathyroid surgery, and equal measurement uncertainty. 
Also, estimation of fractional decrease in PTH and thereby 
clinical interpretation of results during surgery were 
similar using the LDT when compared to both a dedicated 
STAT IO-PTH platform.
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